Skip to main
VALN

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE has modestly increased its assumptions for the commercial uptake of the Lyme vaccine candidate VLA15 in Europe, aligning more closely with higher uptake expectations in the U.S., indicating a positive trend for future revenue generation. Recent reports of strong immune responses following a third yearly booster of VLA15 in both adults and children further bolster the company's potential market position and attractiveness to pharmaceutical partners. Despite a temporary setback with the FDA regarding Ixchiq, the overall financial health remains stable, with earnings aligning with expectations and a focus on developing a robust pipeline of life-saving vaccines.

Bears say

Valneva SE faces significant financial risks stemming from clinical and regulatory setbacks that could adversely impact its revenue generation from marketed vaccines. Recent safety concerns regarding its Ixchiq vaccine have raised competitiveness issues against rival products, particularly Bavarian Nordic's chikungunya vaccine, limiting expected product uptake in Europe. Additionally, the removal of U.S. sales projections for Ixchiq further compounds the company's challenges, suggesting a further deterioration in potential cash flows from product sales.

Valneva SE (VALN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.